Insulet (NASDAQ: PODD) reported fourth-quarter and full-year 2016 earnings after the market closed on Monday. The drug delivery company, which is a leader in tubeless insulin pump technology with its Omnipod Insulin Management System, delivered solid revenue growth of 24% — which exceeded its guidance — while its loss per share narrowed significantly.
Insulet’s stock has gained nearly 45% for the one-year period through the regular trading session on Monday, versus the S&P 500’s total return of 24%.
Metric